Dwelling on Prasugrel: Analysts Debate Prospects for Lilly Clot Drug
This article was originally published in RPM Report
Eli Lilly & Co. devoted a section of its December 6 investor day specifically to the prospects for prasugrel in light of the widespread interest in the product and the presentation of pivotal trial data (TRITON) a month earlier. Here is a sampling of what analysts took away from the meeting.
You may also be interested in...
In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.
Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.
The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.